{
    "clinical_study": {
        "@rank": "53518", 
        "arm_group": [
            {
                "arm_group_label": "S-303 Treated Red Blood Cells (RBC)", 
                "arm_group_type": "Experimental", 
                "description": "Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs.  Each patient will complete both treatment periods."
            }, 
            {
                "arm_group_label": "Conventional, untreated Red Blood Cells", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs.  Each patient will complete both treatment periods."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of S 303 treated red blood cells (RBCs) in subjects who\n      require chronic transfusion support due to thalassemia major."
        }, 
        "brief_title": "Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Thalassemia Major", 
        "condition_browse": {
            "mesh_term": [
                "Beta-Thalassemia", 
                "Thalassemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "To evaluate the efficacy and safety of S 303 treated red blood cells (RBCs) in subjects who\n      require chronic transfusion support due to thalassemia major."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226510 years, of either gender\n\n          -  Diagnosed with thalassemia major and currently participating in a chronic transfusion\n             program\n\n          -  At least a one year history of chronic RBC transfusion support with a stable\n             transfusion requirement (per treating physician)\n\n          -  Intervals of at least 14 days between RBC transfusions\n\n          -  All RBC components are given on one day for each transfusion episode\n\n          -  Negative direct antiglobulin tests (DAT)\n\n          -  Stable iron chelation regimen\n\n          -  Available for measurement of  hemoglobin level at one hour post transfusion\n\n          -  Signed and dated informed consent form\n\n        Exclusion Criteria:\n\n          -  Baseline antibody specific to S 303 treated RBC (positive test, as defined  in\n             Section 8.4.1)\n\n          -  Evidence of splenic hyper function defined as a transfusion requirement >180\n             cc/kg/year  (at 100% hematocrit)\n\n          -  Splenic enlargement: spleen palpable \u22654 cm below costal margin OR \u226518 cm in\n             longitudinal diameter by ultrasound (chosen at the Investigator's discretion\n             according to the data available with ultrasound data being preferable)\n\n          -  Any subject for whom a transition in the number of RBC units transfused is\n             anticipated within 12 months of study entry due to growth of the subject (e.g. a\n             transition from 1 RBC component per transfusion cycle to 2 OR a transition from 2 to\n             3 is anticipated based on weight change alone)\n\n          -  Alloimmunization to high frequency blood group antigens to the extent that the ready\n             provision of compatible blood may not be feasible for the study (alloimmunization\n             alone is not an automatic exclusion)\n\n          -  Current specialized treatment with washed or frozen RBC\n\n          -  Requirement for gamma irradiated RBC components (would present blinding difficulty\n             due to blood component labeling regulations\n\n          -  Treatment with any medication that is known to adversely affect RBC viability\n\n          -  HIV infection (defined as RNA positive)\n\n          -  HCV (hepatitis C)infection (defined as RNA positive) if treated with concomitant\n             medications known to suppress the bone marrow\n\n          -  Pregnant or breast feeding female, or female of child bearing potential not using a\n             medically approved form of contraception\n\n          -  Acute or chronic medical disorder other than thalassemia that, in the opinion of the\n             Investigator or medical monitor, may prevent the subject from completing\n             participation in the study\n\n          -  Participation in another clinical study, either concurrently or within the previous\n             28 days, in which the study drug or device may influence red blood cell viability"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01740531", 
            "org_study_id": "CLI 00076"
        }, 
        "intervention": [
            {
                "arm_group_label": "S-303 Treated Red Blood Cells (RBC)", 
                "intervention_name": "S-303 Treated Red Blood Cells (RBCs)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Conventional, untreated Red Blood Cells", 
                "intervention_name": "Conventional, untreated Red Blood Cells", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "S303 treated RBCs", 
        "lastchanged_date": "June 5, 2013", 
        "location": [
            {
                "contact": {
                    "email": "secondacasella@hotmail.com", 
                    "last_name": "Raffaella Origa, MD", 
                    "phone": "0039 340 2453099"
                }, 
                "facility": {
                    "address": {
                        "city": "Cagliari", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Regionale per le Microcitemie Azienda"
                }, 
                "investigator": {
                    "last_name": "Raffaella Origa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "antonio.piga@unito.it", 
                    "last_name": "Antonio Piga, MD", 
                    "phone": "39 011 9026854"
                }, 
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy"
                    }, 
                    "name": "University of Torino"
                }, 
                "investigator": {
                    "last_name": "Antonio Piga, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Study to Evaluate Efficacy and Safety of S 303 Treated Red Blood Cells (RBC) in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion", 
        "overall_contact": {
            "email": "secondacasella@hotmail.com", 
            "last_name": "Raffaella Origa, MD", 
            "phone": "39 340 2453099"
        }, 
        "overall_contact_backup": {
            "email": "antonio.piga@unito.it", 
            "last_name": "Antonio Piga, MD", 
            "phone": "39 011 9026854"
        }, 
        "overall_official": [
            {
                "affiliation": "Ospedale Regionale per le Microcitemie azienda", 
                "last_name": "Raffaella Origa, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Torino", 
                "last_name": "Antonio Piga, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Hemoglobin consumption measured as total hemoglobin mass transfused per subject adjusted for average body weight and the number of days during the efficacy evaluation period (adjusted hemoglobin (Hgb) consumption units are g Hgb/kg body weight/day).", 
                "measure": "Primary Efficacy Endpoint - Hemoglobin consumption", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Incidence of a treatment-emergent antibody with confirmed specificity to S 303 treated red blood cells (RBC) associated with clinically significant hemolysis", 
                "measure": "Primary Safety Endpoint-Incidence of a treatment-emergent antibody with confirmed specificity to S 303 treated red blood cells (RBC)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01740531"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Hemoglobin increment one hour post-transfusion", 
                "measure": "Secondary Efficacy Endpoint-Hemoglobin increment", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Proportional decline in post transfusion hemoglobin level per day (%/day)", 
                "measure": "Secondary Efficacy Endpoint-Proportional decline in post transfusion hemoglobin level per day (%/day)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Subjects will be actively monitored for adverse events during the transfusion episode and until discharge from the transfusion clinic.", 
                "measure": "Secondary Safety Endpoint-Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Transfusion reactions within 24 hours of a study transfusion with the assigned study product.", 
                "measure": "Secondary Safety Endpoint-Transfusion reactions within 24 hours", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "description": "Frequency of allo immunization to red blood cell (RBC) allo-antigens", 
                "measure": "Secondary Safety Endpoint-Frequency of allo immunization to red blood cell (RBC) allo-antigens", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Cerus Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cerus Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}